Graft-Versus-Host Disease Clinical Trials

36 recruitingLast updated: June 18, 2026

There are 36 actively recruiting graft-versus-host disease clinical trials across 12 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3. Top locations include Boston, Massachusetts, United States, Shanghai, Shanghai Municipality, China, Bethesda, Maryland, United States. Updated daily from ClinicalTrials.gov.


Graft-Versus-Host Disease Trials at a Glance

36 actively recruiting trials for graft-versus-host disease are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 15 trials, with the heaviest enrollment activity in Boston, Shanghai, and Bethesda. Lead sponsors running graft-versus-host disease studies include Memorial Sloan Kettering Cancer Center, City of Hope Medical Center, and Novartis Pharmaceuticals.

Browse graft-versus-host disease trials by phase

Treatments under study

About Graft-Versus-Host Disease Clinical Trials

Looking for clinical trials for Graft-Versus-Host Disease? There are currently 28 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Graft-Versus-Host Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Graft-Versus-Host Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 36 trials

Recruiting

A Study of Ruxolitinib in Patients With Graft-Versus Host Disease

Graft-Versus-Host Disease
Novartis Pharmaceuticals395 enrolled1 locationNCT07594587
Recruiting

Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

Graft-Versus-Host DiseaseGraft-versus-leukemiaDonor Apheresis
National Heart, Lung, and Blood Institute (NHLBI)500 enrolled1 locationNCT00001529
Recruiting

Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls

Graft-Versus-Host Disease
National Institute of Dental and Craniofacial Research (NIDCR)500 enrolled1 locationNCT03602599
Recruiting
Phase 1Phase 2

Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

Graft-Versus-Host Disease
Northwell Health74 enrolled1 locationNCT05289167
Recruiting
Phase 2

A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant

GvHDUndefinedGraft-Versus-Host Disease
Memorial Sloan Kettering Cancer Center44 enrolled9 locationsNCT05675930
Recruiting
Phase 2

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

Acute Lymphoblastic LeukemiaHodgkin LymphomaNon-Hodgkin Lymphoma+5 more
Memorial Sloan Kettering Cancer Center71 enrolled1 locationNCT07566377
Recruiting
Phase 1

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Acute Myeloid LeukemiaMyelodysplastic SyndromeGraft-Versus-Host Disease
City of Hope Medical Center15 enrolled1 locationNCT06996119
Recruiting
Phase 2

Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Acute Graft Versus Host DiseaseGraft-Versus-Host DiseaseALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology42 enrolled1 locationNCT07572669
Recruiting
Phase 1

Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Graft vs Host DiseaseGraft-Versus-Host Disease
Washington University School of Medicine41 enrolled1 locationNCT06008808
Recruiting
Phase 2

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

T-cell LymphomaT-cell Prolymphocytic LeukemiaLymphoma, T-Cell+5 more
Jonathan Brammer44 enrolled1 locationNCT07356245
Recruiting
Phase 2

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

Hematologic MalignancyGraft vs Host DiseaseGraft-Versus-Host Disease
Memorial Sloan Kettering Cancer Center46 enrolled8 locationsNCT07006506
Recruiting
Phase 2

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Chronic Graft-Versus-Host Disease (cGVHD)
H. Lee Moffitt Cancer Center and Research Institute120 enrolled5 locationsNCT06660355
Recruiting
Not Applicable

A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

Graft vs Host DiseaseGraft-Versus-Host Disease
Christopher Dvorak90 enrolled1 locationNCT04337515
Recruiting
Not Applicable

A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD

Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)
Anhui Provincial Hospital12 enrolled1 locationNCT06321198
Recruiting
Phase 3

Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation

Allogeneic Hematopoietic Cell TransplantGraft-Versus-Host Disease
Shanghai Jiao Tong University School of Medicine316 enrolled1 locationNCT06705062
Recruiting
Not Applicable

Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease

Graft-Versus-Host DiseaseBone Marrow Transplant Complications
Massachusetts General Hospital350 enrolled2 locationsNCT06910969
Recruiting
Phase 1

PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

Graft-Versus-Host Disease
Henry Ford Health System18 enrolled1 locationNCT04886726
Recruiting
Phase 1

Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia

Graft-Versus-Host DiseaseXerostomiaSjogren's Disease
University of Wisconsin, Madison36 enrolled1 locationNCT06392711
Recruiting
Phase 2

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

Hematologic MalignancyGraft-Versus-Host Disease
Nantes University Hospital82 enrolled3 locationsNCT06252870
Recruiting

Relationship Between "FODMAPs" and "GVHD"

Graft-Versus-Host Disease
The First Affiliated Hospital of Soochow University100 enrolled1 locationNCT04660487